14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Feb 25, 2026
CLSD vs CASI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CASI Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–2 Matrix Metrics)
CASI Overall Winner
6-Pillar Tally: CLSD 1 – 3 CASI (2 Tie)
Matrix Metrics: CLSD 2 – 5 CASI
As of Feb 25, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin).
Technical & Structure Timing Caution: CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs CASI. Trailing 12-month operating profitability (CLSD -3502.5% vs CASI -333.1%) and valuation multiples (CLSD N/M vs CASI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CASI Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.4M market capitalization and -333.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLSD vs CASI Key Questions & Quantitative Answers
As of Feb 25, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin). Technical & Structure Timing Caution: CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CASI leads the Growth & Scale pillar: CLSD posts -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin), compared with CASI at -60.5% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (35.8% gross margin, -333.1% operating margin). On trailing 12-month operating scale, CLSD generates $3.3M in USD-normalized revenue versus $27M for CASI. In operating R&D and SG&A reinvestment, CLSD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CASI.
CASI screens cheaper on headline valuation multiples. CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin), whereas CASI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLSD (-1310.0% ROE) versus CASI (-1094.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk). By comparison, CASI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 240% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 25, 2026. For educational research only; not investment advice.